Drospirenone | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | |
Drospirenone | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | |
Drospirenone | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | |
Drospirenone | hsa04015 | Rap1 signaling pathway | 3.07E-02 | 4 | P25116, Q8TEU7, P08514, P17252 | F2R, RAPGEF6, ITGA2B, PRKCA | More | |
Drospirenone | hsa04064 | NF-kappa B signaling pathway | 1.09E-04 | 11 | P10415, Q13489, O00463, Q13546, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341, Q9UNE0 | BCL2, BIRC3, TRAF5, RIPK1, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1, EDAR | More | |
Drospirenone | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 5 | P21453, Q9H228, Q13362, Q9BX95, P10415 | S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | |
Drospirenone | hsa04080 | Neuroactive ligand-receptor interaction | 1.00E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | |
Drospirenone | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
Drospirenone | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | |
Drospirenone | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | |
Drospirenone | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | |
Drospirenone | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | |
Drospirenone | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | |
Drospirenone | hsa04217 | Necroptosis | 2.93E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | |
Drospirenone | hsa04340 | Hedgehog signaling pathway | 3.09E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | |
Drospirenone | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
Drospirenone | hsa04611 | Platelet activation | 3.39E-02 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | |
Drospirenone | hsa04612 | Antigen processing and presentation | 4.48E-02 | 5 | P13765, P26715, P26717, Q13241, P01732 | HLA-DOB, KLRC1, KLRC2, KLRD1, CD8A | More | |
Drospirenone | hsa04613 | Neutrophil extracellular trap formation | 4.93E-02 | 8 | O60603, P05164, P08246, Q9UM07, Q15080, P20160, P08311, P21730 | TLR2, MPO, ELA2, PADI4, NCF4, AZU1, CTSG, C5AR1 | More | |
Drospirenone | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | |
Drospirenone | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | |
Drospirenone | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
Drospirenone | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
Drospirenone | hsa04650 | Natural killer cell mediated cytotoxicity | 2.02E-03 | 9 | P16298, P50591, O60880, P20963, Q02750, Q13241, P26718, P26717, P26715 | PPP3CB, TNFSF10, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, KLRC2, KLRC1 | More | |
Drospirenone | hsa04658 | Th1 and Th2 cell differentiation | 1.07E-03 | 7 | Q04759, P20963, P09693, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, STAT4, GATA3, TBX21, HLA-DOB | More | |
Drospirenone | hsa04659 | Th17 cell differentiation | 1.90E-02 | 6 | Q04759, P13765, Q9UL17, P23771, P09693, P20963 | PRKCQ, HLA-DOB, TBX21, GATA3, CD3G, CD247 | More | |
Drospirenone | hsa04660 | T cell receptor signaling pathway | 1.00E-02 | 7 | Q9UDY8, Q04759, P10747, Q08881, P20963, P09693, P01732 | MALT1, PRKCQ, CD28, ITK, CD247, CD3G, CD8A | More | |
Drospirenone | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | |
Drospirenone | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
Drospirenone | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | |
Drospirenone | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | |
Drospirenone | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | |
Drospirenone | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
Drospirenone | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.23E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | |
Drospirenone | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | |
Drospirenone | hsa05132 | Salmonella infection | 9.85E-03 | 4 | Q13546, Q13489, O60282, P68371 | RIPK1, BIRC3, KIF5C, TUBB2C | More | |
Drospirenone | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | |
Drospirenone | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | |
Drospirenone | hsa05202 | Transcriptional misregulation in cancer | 2.90E-02 | 9 | Q12778, Q13315, P14780, Q16548, O15550, P05164, P08246, Q9C0K0, P24522 | FOXO1, ATM, MMP9, BCL2A1, UTX, MPO, ELA2, BCL11B, GADD45A | More | |
Drospirenone | hsa05205 | Proteoglycans in cancer | 4.46E-02 | 4 | Q12955, Q14247, P17252, P08962 | ANK3, CTTN, PRKCA, CD63 | More | |
Drospirenone | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | |
Drospirenone | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | |
Drospirenone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.84E-02 | 5 | P20963, P09693, O60603, P10747, Q04759 | CD247, CD3G, TLR2, CD28, PRKCQ | More | |
Drospirenone | hsa05310 | Asthma | 1.35E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
Drospirenone | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
Drospirenone | hsa05321 | Inflammatory bowel disease | 1.17E-03 | 5 | O60603, P13765, Q14765, Q9UL17, P23771 | TLR2, HLA-DOB, STAT4, TBX21, GATA3 | More | |
Drospirenone | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | |
Drospirenone | hsa05330 | Allograft rejection | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
Drospirenone | hsa05332 | Graft-versus-host disease | 3.45E-03 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | |
Drospirenone | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.82E-02 | 3 | P14923, P08514, Q9UJU2 | JUP, ITGA2B, LEF1 | More | |
Drospirenone | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |